Pharma

Your Article Summary

See Latest Articles

ImmunoGen, Inc. Announces Exercise of Over-allotment Option
ImmunoGen, Inc., 06/23/09

ImmunoGen, Inc. , a biopharmaceutical company that develops targeted anticancer therapeutics, announced that the underwriters of its previously announced public offering of common stock have exercised in full their option to purchase 750,000 shares of common stock at a public offering price of $7.00 per share. The exercise of the over-allotment option brings the total shares of common stock to be sold by ImmunoGen in the offering to 5,750,000 shares.

Today in Research & Development...keeping you current

Receive free subspecialty "5-minute updates" via email

GlaxoSmithKline and NanoBio announce OTC licensing agreement for cold sore treatment
GlaxoSmithKline, 12/18/09

ARIAD Announces Full Enrollment in Phase 3 Succeed Trial Evaluating Ridaforolimus in Patients with Metastatic Sarcomas
ARIAD Pharmaceuticals, 12/18/09

CCHIT Appoints Officers
HealthDataManagement, 12/18/09

 See all of Research & Development